A First-in-human, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumor Activity of SYN818, a DNA Polymerase Theta (POLQ) Inhibitor Alone in Patients with Locally Advanced or Metastatic Solid Tumors
Latest Information Update: 06 Nov 2024
Price :
$35 *
At a glance
- Drugs SYN 818 (Primary)
- Indications Breast cancer; Ovarian cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors SynRx Therapeutics
- 05 Nov 2024 New trial record